RESUMEN
Disseminated infection by Hormographiella aspergillata is extremely rare and small intestine involvement has not been reported previously. A 51-year-old man with myelodysplastic syndrome developed pneumonia after cord blood cell transplantation. Fungal growth from the biopsied lung was identified as H. aspergillata by morphology and the gene analysis. Although antifungal agents including voriconazole and liposomal amphotericin B were administered, he died of disseminated H. aspergillata infection. We review the literature and discuss the treatment and prognosis.
Asunto(s)
Agaricales/patogenicidad , Antifúngicos/uso terapéutico , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Terapia de Inmunosupresión/efectos adversos , Infecciones Fúngicas Invasoras/microbiología , Enfermedades Raras/microbiología , Agaricales/genética , Agaricales/aislamiento & purificación , Antifúngicos/administración & dosificación , Encéfalo/diagnóstico por imagen , Encéfalo/patología , Infecciones Fúngicas del Sistema Nervioso Central/sangre , Infecciones Fúngicas del Sistema Nervioso Central/tratamiento farmacológico , Infecciones Fúngicas del Sistema Nervioso Central/etiología , Infecciones Fúngicas del Sistema Nervioso Central/patología , ADN de Hongos , Enfermedad Injerto contra Huésped/prevención & control , Humanos , Terapia de Inmunosupresión/métodos , Inmunosupresores/administración & dosificación , Inmunosupresores/uso terapéutico , Enfermedades Intestinales/sangre , Enfermedades Intestinales/tratamiento farmacológico , Enfermedades Intestinales/etiología , Enfermedades Intestinales/patología , Intestino Delgado/patología , Infecciones Fúngicas Invasoras/sangre , Infecciones Fúngicas Invasoras/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/sangre , Enfermedades Pulmonares Fúngicas/tratamiento farmacológico , Enfermedades Pulmonares Fúngicas/etiología , Enfermedades Pulmonares Fúngicas/patología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Síndromes Mielodisplásicos/cirugía , Neutropenia/tratamiento farmacológico , Neutropenia/etiología , Neutropenia/microbiología , Enfermedades Raras/sangre , Enfermedades Raras/tratamiento farmacológico , Análisis de Secuencia de ADN , Tomografía Computarizada por Rayos X , Acondicionamiento Pretrasplante/efectos adversos , Acondicionamiento Pretrasplante/métodos , Trasplante Homólogo/efectos adversosRESUMEN
OBJECTIVE: Bright light therapy is widely used as the treatment of choice for seasonal affective disorder. Nonetheless, our understanding of the mechanisms of bright light is limited and it is important to investigate the mechanisms. The purpose of this study is to examine the hypothesis that bright light exposure may increase [(18) F]-fluorodeoxyglucose (FDG) uptake in olfactory bulb and/or hippocampus which may be associated neurogenesis in the human brain. METHOD: A randomized controlled trial comparing 5-day bright light exposure + environmental light (bright light exposure group) with environmental light alone (no intervention group) was performed for 55 participants in a university hospital. The uptake of [(18) F]FDG in olfactory bulb and hippocampus using FDG positron emission tomography was compared between two groups. RESULTS: There was a significant increase of uptake in both right and left olfactory bulb for bright light exposure group vs. no intervention group. After adjustment of log-transformed illuminance, there remained a significant increase of uptake in the right olfactory bulb. CONCLUSION: The present findings suggest a possibility that 5-day bright light exposure may increase [(18) F]FDG in the right olfactory bulb of the human brain, suggesting a possibility of neurogenesis. Further studies are warranted to directly confirm this possibility.
Asunto(s)
Fluorodesoxiglucosa F18/farmacocinética , Hipocampo/metabolismo , Hipocampo/efectos de la radiación , Bulbo Olfatorio/metabolismo , Bulbo Olfatorio/efectos de la radiación , Trastorno Afectivo Estacional/metabolismo , Trastorno Afectivo Estacional/terapia , Adulto , Femenino , Hipocampo/efectos de los fármacos , Humanos , Luz , Masculino , Persona de Mediana Edad , Bulbo Olfatorio/diagnóstico por imagen , Fototerapia/métodos , Tomografía de Emisión de Positrones/métodos , Radiofármacos/farmacocinética , Trastorno Afectivo Estacional/diagnóstico por imagen , Resultado del Tratamiento , Adulto JovenRESUMEN
To find a new anti-malarial medicine derived from natural resources, we examined the leaves of 13 common Japanese plants in vitro. Among them, a leaf-extract of Hydrangea macrophylla, a common Japanese flower, inhibited the parasitic growth of Plasmodium falciparum. The IC50 of Hydrangea macrophylla leaf extract to Plasmodium falciparum was 0.18 microg/ml. The IC50 to NIH 3T3-3 cells, from a normal mouse cell line, was 7.2 microg/ml. Thus, selective toxicity was 40. For the in vivo test, we inoculated Plasmodium berghei, a rodent malaria parasite, to ddY mice and administered the leaf-extract of Hydrangea macrophylla (3.6 mg/0.2 ml) orally 3 times a day for 3 days. Malaria parasites did not appear in the blood of in the treated mice, but they did appear in the control group on day 3 or 4 after inoculation with the parasites. When leaf extract was administered to 5 mice 2 times a day for 3 days, malaria parasites did not appear in 4 of the mice but did appear in 1 mouse. In addition, the leaf-extract was administered orally 3 times a day for 3 days to Plasmodium berghei infected mice with a parasitemia of 2.7%. In the latter group, malaria parasites disappeared on day 3 after initiating the treatment, but they appeared again after day 5 or 6. Although we could not cure the mice entirely, we confirmed that the Hydrangea macrophylla leaf extract did contain an anti-malarial substance that can be administered orally.
Asunto(s)
Antimaláricos/farmacología , Plantas Medicinales , Animales , Antimaláricos/uso terapéutico , Japón , Malaria/tratamiento farmacológico , Ratones , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Plasmodium berghei/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacosRESUMEN
White kidney bean (Phaseolus vulgaris) contains two kinds of alpha-amylase inhibitors, one heat-stable (alpha AI-s) and one heat-labile (alpha AI-u). alpha AI-s has recently been revealed to be a tetrameric complex, alpha(2)beta(2), with two active sites [Kasahara et al. (1996) J. Biochem. 120, 177-183]. The present study was undertaken to reveal the molecular features of alpha AI-u, which is composed of three kinds of subunits, alpha, beta, and gamma. The gamma-subunit, in contrast to the alpha- and beta-subunits that are indistinguishable from the alpha- and beta-subunits of alpha AI-s, was found to correspond to a subunit of an alpha-amylase inhibitor-like protein, which has been identified as an inactive, evolutionary intermediate between arcelin and the alpha-amylase inhibitor in a P. vulgaris defense protein family. The polypeptide molecular weight of alpha AI-u determined by the light-scattering technique, together with the polypeptide molecular weights of the subunits, suggests that alpha AI-u is a trimeric complex, alpha beta gamma. The inhibition of alpha AI-u by increasing amounts of porcine pancreatic alpha-amylase (PPA) indicates that an inactive 1:1 complex is formed between alpha AI-u and PPA. Molecular weight estimation of the complex by the light-scattering technique confirmed that it is a complex of alpha AI-u with one PPA molecule. Thus it seems probable that alpha AI-u is an evolutionary intermediate of the P. vulgaris alpha-amylase inhibitor.
Asunto(s)
Evolución Molecular , Fabaceae/química , Proteínas de Plantas/química , Plantas Medicinales , Secuencia de Aminoácidos , Datos de Secuencia Molecular , Peso Molecular , Proteínas de Plantas/aislamiento & purificación , Proteínas de Plantas/metabolismo , Homología de Secuencia de Aminoácido , Inhibidores de Tripsina , alfa-Amilasas/antagonistas & inhibidores , alfa-Amilasas/aislamiento & purificación , alfa-Amilasas/metabolismoRESUMEN
Antimalarial screening was performed for microbial metabolites that simulate artemisinin in their mode of action, a potent antimalarial component of an herbal remedy with a characteristic peroxide structure. Nanaomycin A was identified in this screen as an antimalarial compound, together with radicicol and several other compounds already reported (J. Antibiotics 51: 153 approximately 160, 1998). Nanaomycin A inhibited in vitro growth of the human malaria parasite Plasmodium falciparum with an IC80 value of 33.1 nM. It was as potent as radicicol and about 1/10 as potent as artemisinin. Studies on the mode of action suggested that the antimalarial action of the two non-peroxides, nanaomycin A and radicicol, involved heme-dependent radical generation, as is for the peroxide artemisinin. Namely, the inhibition of in vitro growth of malaria parasite by nanaomycin A or radicicol was reversed by tocopherol, a radical scavenger added to the assay mixture. Secondly, in a reaction system established for radical detection, in which a test radical donor and beta-alanylhistidine as a radical recipient were incubated with and without hemin, the two compounds caused heme-dependent decreases of beta-alanylhistidine, as did artemisinin. Among the 14 microbial metabolites identified during this screening, a correlation was observed between antimalarial activity and heme-dependent radical generating activity.
Asunto(s)
Antimaláricos/farmacología , Artemisininas , Hemina/metabolismo , Lactonas/farmacología , Naftoquinonas/farmacología , Plasmodium falciparum/efectos de los fármacos , Animales , Antimaláricos/aislamiento & purificación , Carnosina/metabolismo , Evaluación Preclínica de Medicamentos , Humanos , Lactonas/aislamiento & purificación , Macrólidos , Estructura Molecular , Naftoquinonas/aislamiento & purificación , Plasmodium falciparum/metabolismo , Sesquiterpenos/farmacología , Relación Estructura-ActividadRESUMEN
The therapeutic effect of methylcobalamin (Met-12) on sleep-wake rhythm disorders was examined in a double-blind test. In the test group which was given a large dosage, a higher percentage of improvement was found compared to the control group with a small dosage, although the difference was not significant. The test group inconsistently showed significant improvement in both the sleep-wake cycle parameters and in clinical symptoms. The tendency was for the results to show a beneficial effect of Met-12 on rhythm disorders. However, because the percentage of improvement was low and significant improvement was inconsistent, Met-12 might be considered to have a low therapeutic potency and possible use as a booster for other treatment methods of the disorders.
Asunto(s)
Fases del Sueño/efectos de los fármacos , Trastornos del Sueño-Vigilia/tratamiento farmacológico , Vitamina B 12/análogos & derivados , Vigilia/efectos de los fármacos , Afecto/efectos de los fármacos , Nivel de Alerta/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Humanos , Trastornos del Sueño-Vigilia/diagnóstico , Resultado del Tratamiento , Vitamina B 12/administración & dosificaciónRESUMEN
In anovulatory patients ovulation is usually induced by clomiphene citrate (CC) or gonadotropin therapy, but in the case of polycystic ovary syndrome (PCOS), diagnosed by the presence of several micropolycysts in the ovaries and a high LH/FSH ratio in the serum, CC is only minimally effective, and side effects are often a problem with gonadotropin therapy. In the present study we administered a Chinese herbal medicine Sairei-to which appears to have a steroidal effect in anovulatory PCOS patients. As a result of the treatment, serum LH and the LH/FSH ratio significantly decreased (P<0.01) and the ovulatory rate was 70.6%. Serum testosterone levels were within normal limits before the treatment, and did not significantly change during the treatment. Sairei-to may therefore be useful for the treatment of anovulation in PCOS patients.
Asunto(s)
Anovulación/tratamiento farmacológico , Medicamentos Herbarios Chinos/uso terapéutico , Inducción de la Ovulación , Síndrome del Ovario Poliquístico/complicaciones , Anovulación/etiología , Índice de Masa Corporal , Femenino , Hormona Folículo Estimulante/sangre , Humanos , Hormona Luteinizante/sangre , Síndrome del Ovario Poliquístico/sangreRESUMEN
Curcumin, a major component of turmeric, a seasoning commonly used in Indian food, and a known antioxidant, anti-inflammatory and anti-carcinogenic agent, is a potent stimulator of the stress-induced expression of Hsp27, alphaB crystallin and Hsp70. When C6 rat glioma cells were exposed to arsenite (100 microM for 1 h), CdCl2 (100 microM for 1 h) or heat (42 degrees C for 30 min) in the presence of 3-10 microM curcumin, induction of the synthesis of all three proteins was markedly stimulated, as detected by specific immunoassays, Western blot analysis and Northern blot analysis. A gel mobility shift assay revealed that curcumin prolonged the stress-induced activation of the heat shock element-binding (HSE-binding) activity of heat shock transcription factor (Hsf) in the cultured cells. The stimulatory effect of curcumin on the responses to stress was also observed in BRL-3A rat liver cells and Swiss 3T3 mouse fibroblasts. Induction of Hsp27, alphaB crystallin and Hsp70 in the liver and adrenal glands of heat-stressed (42 degrees C for 20 min) rats was also enhanced by prior injection of curcumin (20 mg/kg body weight). As curcumin is a potent inhibitor of arachidonic acid metabolism, it is suggested that the mechanism of the stimulation by curcumin of the stress responses might be similar to that of salicylate, indomethacin and nordihydroguaiaretic acid.
Asunto(s)
Antioxidantes/farmacología , Curcumina/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Proteínas de Choque Térmico/biosíntesis , Estrés Fisiológico/genética , Células 3T3/efectos de los fármacos , Células 3T3/metabolismo , Glándulas Suprarrenales/efectos de los fármacos , Glándulas Suprarrenales/metabolismo , Animales , Arsenitos/toxicidad , Neoplasias Encefálicas/patología , Células Cultivadas , Cristalinas/biosíntesis , Cristalinas/genética , Curcuma , Glioma/patología , Proteínas HSP70 de Choque Térmico/biosíntesis , Proteínas HSP70 de Choque Térmico/genética , Proteínas de Choque Térmico/genética , Calor , Hígado/citología , Masculino , Ratones , Extractos Vegetales/química , ARN Mensajero/biosíntesis , ARN Mensajero/genética , Ratas , Ratas Wistar , Compuestos de Sodio/toxicidad , Estimulación Química , Estrés Fisiológico/inducido químicamente , Estrés Fisiológico/metabolismo , Células Tumorales Cultivadas/efectos de los fármacosRESUMEN
Effects of NB-818, a new Ca2+ entry blocker, on a transient cerebral ischemic model in Mongolian gerbils were examined. Following bilateral common carotid arteries occlusion of 20 min duration, all the control animals died within 24 hr after reperfusion. The administration of NB-818 at 0.1 mg/kg, i.p., 30 min after reperfusion significantly reduced the mortality rate to 65.0% (P less than 0.01); and 0.01 mg/kg, i.p., had a tendency to reduce the mortality rate. In the nimodipine-treated groups, a similar effects in the ischemic model. Furthermore, the administration of NB-818 at 0.1 mg/kg, i.p., 15 min before occlusion also had a tendency to reduce the mortality rate. On the incidences of seizures induced by transient cerebral ischemia, there were no significant differences between each of the drug-treated groups and the control group. In NB-818 and nimodipine-treated groups, the morbidity scores NB-818 and nimodipine in this severe cerebral ischemic model have advantages over those of nicardipine and flunarizine. Thus, these results suggest that NB-818 may be useful in the treatment of ischemic cerebral damage.